RT Journal Article
SR Electronic
T1 Long-term Results of a Phase II Study of S-1 plus Irinotecan in Metastatic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4157
OP 4161
VO 32
IS 9
A1 IWASA, SATORU
A1 YAMADA, YASUHIDE
A1 KATO, KEN
A1 GOTO, AYUMU
A1 HONMA, YOSHITAKA
A1 HAMAGUCHI, TETSUYA
A1 SHIMADA, YASUHIRO
YR 2012
UL http://ar.iiarjournals.org/content/32/9/4157.abstract
AB Aim: The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer. Patients and Methods: Between April 2004 and February 2005, 41 patients with previously untreated advanced or recurrent colorectal cancer were enrolled in the study. Chemotherapy consisted of oral administration in S-1 at 40 mg/m2 twice daily on days 1 to 14 and intravenous infusion of irinotecan at 150 mg/m2 on day 1 in a 21-day cycle. Results: The median patient follow-up was 78.0 months. The median survival time was 23.7 months, and the 2-year survival rate was 50%. The median time to tumor progression was 8.3 months. Conclusion: The results of this long-term update confirmed that first-line combination therapy with oral S-1 plus irinotecan was effective in patients with metastatic colorectal cancer.